Features - Interviews, Oncology

Filter

Current filters:

InterviewsOncology

Popular Filters

Executive Q&A: Paul Higham, CEO of immatics

Executive Q&A: Paul Higham, CEO of immatics

27-05-2014

In an interview with The Pharma Letter, immatics chief executive Paul Higham discusses the company's…

BiotechnologyCancerGermanyHealth Medical Pharmaimmatics biotechnologiesImmunologyInterviewsMedicineOncologyVaccination

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

11-04-2014

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism.…

AstraZenecaInterviewsIressaOncologyPharmaceuticalUK

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

01-04-2014

The Pharma Letter interviewed chief executive Dr Thomas Taapken about Epigenomics’ lead product, increasing…

BiotechnologyEpi proColonEpigenomicsGermanyInterviewsOncology

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

19-03-2014

In an interview with The Pharma Letter, CEO Michael Forer discusses ADC Therapeutics' developing pipeline…

ADC TherapeuticsBiotechnologyInterviewsNorthern EuropeOncology

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

17-03-2014

The president of pharma giant Merck & Co’s (NYSE: MRK) operations in Europe and Canada Bruno Strigini…

Anti-viralsCanadaDiabetesEuropeInterviewsMerck & CoMK-3475OncologyPharmaceuticalRegulationUKVaccines

Interview: Clinigen’s CEO Peter George on the company’s record growth

Interview: Clinigen’s CEO Peter George on the company’s record growth

15-11-2013

If there is one pharma company bucking the trend of shaky financial results it is the Clinigen Group.

BoardroomClinigen GroupFoscavirInterviewsOncologyPharmaceuticalRare diseasesUK

IN FOCUS: Using the body’s own defenses against cancer - Scancell reveals its immunotherapy products

IN FOCUS: Using the body’s own defenses against cancer - Scancell reveals its immunotherapy products

07-10-2013

UK-based cancer therapeutics firm Scancell, developer of novel immunotherapies, gathered its investors…

BiotechnologyEuropeFinancialInterviewsOncologyScancell

IN FOCUS: Boehringer Ingelheim presents its

IN FOCUS: Boehringer Ingelheim presents its "long and healthy" R&D pipeline

02-08-2013

German family-owned drug major Boehringer Ingelheim presented its major pipeline developments at an R&D…

afatinibBoehringer IngelheimDiabetesEuropeInterviewslinagliptinnintedanibOncologyPharmaceuticalResearchRespiratory and Pulmonaryvolasertib

Company Spotlight

ImmunoGen

ImmunoGen

Back to top